Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 2
2005 2
2006 2
2007 2
2011 1
2012 3
2013 5
2014 4
2015 3
2016 3
2018 2
2019 2
2020 2
2021 5
2022 5
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers.
Fidelle M, Rauber C, Alves Costa Silva C, Tian AL, Lahmar I, de La Varende AM, Zhao L, Thelemaque C, Lebhar I, Messaoudene M, Pizzato E, Birebent R, Mbogning Fonkou MD, Zoppi S, Reni A, Dalban C, Leduc M, Ferrere G, Durand S, Ly P, Silvin A, Mulder K, Dutertre CA, Ginhoux F, Yonekura S, Roberti MP, Tidjani-Alou M, Terrisse S, Chen J, Kepp O, Schippers A, Wagner N, Suárez-Gosálvez J, Kobold S, Fahrner JE, Richard C, Bosq J, Lordello L, Vitali G, Galleron N, Quinquis B, Le Chatelier E, Blanchard L, Girard JP, Jarry A, Gervois N, Godefroy E, Labarrière N, Koschny R, Daillère R, Besse B, Truntzer C, Ghiringhelli F, Coatnoan N, Mhanna V, Klatzmann D, Drubay D, Albiges L, Thomas AM, Segata N, Danlos FX, Marabelle A, Routy B, Derosa L, Kroemer G, Zitvogel L. Fidelle M, et al. Among authors: dalban c. Science. 2023 Jun 9;380(6649):eabo2296. doi: 10.1126/science.abo2296. Epub 2023 Jun 9. Science. 2023. PMID: 37289890
Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer.
Cassier PA, Navaridas R, Bellina M, Rama N, Ducarouge B, Hernandez-Vargas H, Delord JP, Lengrand J, Paradisi A, Fattet L, Garin G, Gheit H, Dalban C, Pastushenko I, Neves D, Jelin R, Gadot N, Braissand N, Léon S, Degletagne C, Matias-Guiu X, Devouassoux-Shisheboran M, Mery-Lamarche E, Allard J, Zindy E, Decaestecker C, Salmon I, Perol D, Dolcet X, Ray-Coquard I, Blanpain C, Bernet A, Mehlen P. Cassier PA, et al. Among authors: dalban c. Nature. 2023 Aug;620(7973):409-416. doi: 10.1038/s41586-023-06367-z. Epub 2023 Aug 2. Nature. 2023. PMID: 37532934 Free PMC article. Clinical Trial.
PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients.
Gauduchon T, Kfoury M, Lorusso D, Floquet A, Ventriglia J, Salaun H, Moubarak M, Rivoirard R, Polastro L, Favier L, You B, Berton D, de la Motte Rouge T, Mansi L, Abdeddaim C, Prulhiere K, Lancry Lecomte L, Provansal M, Dalban C, Ray-Coquard I. Gauduchon T, et al. Among authors: dalban c. Gynecol Oncol. 2023 Jun;173:98-105. doi: 10.1016/j.ygyno.2023.04.002. Epub 2023 Apr 25. Gynecol Oncol. 2023. PMID: 37105063
Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.
Heudel P, Frenel JS, Dalban C, Bazan F, Joly F, Arnaud A, Abdeddaim C, Chevalier-Place A, Augereau P, Pautier P, Chakiba C, You B, Lancry-Lecomte L, Garin G, Marcel V, Diaz JJ, Treilleux I, Pérol D, Fabbro M, Ray-Coquard I. Heudel P, et al. Among authors: dalban c. JAMA Oncol. 2022 Jul 1;8(7):1001-1009. doi: 10.1001/jamaoncol.2022.1047. JAMA Oncol. 2022. PMID: 35551299 Free PMC article. Clinical Trial.
Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study.
Velev M, Dalban C, Chevreau C, Gravis G, Negrier S, Laguerre B, Gross-Goupil M, Ladoire S, Borchiellini D, Geoffrois L, Joly F, Priou F, Barthelemy P, Laramas M, Narciso B, Thiery-Vuillemin A, Berdah JF, Ferrari V, Dominique Thomas Q, Mione C, Curcio H, Oudard S, Tantot F, Escudier B, Chabaud S, Albiges L, Thibault C. Velev M, et al. Among authors: dalban c. Eur J Cancer. 2023 Mar;182:66-76. doi: 10.1016/j.ejca.2022.12.028. Epub 2023 Jan 13. Eur J Cancer. 2023. PMID: 36746010 Clinical Trial.
No Geographical Inequalities in Survival for Sarcoma Patients in France: A Reference Networks' Outcome?
Fayet Y, Chevreau C, Decanter G, Dalban C, Meeus P, Carrère S, Haddag-Miliani L, Le Loarer F, Causeret S, Orbach D, Kind M, Le Nail LR, Ferron G, Labrosse H, Chaigneau L, Bertucci F, Ruzic JC, Le Brun Ly V, Farsi F, Bompas E, Noal S, Vozy A, Ducoulombier A, Bonnet C, Chabaud S, Ducimetière F, Tlemsani C, Ropars M, Collard O, Michelin P, Gantzer J, Dubray-Longeras P, Rios M, Soibinet P, Le Cesne A, Duffaud F, Karanian M, Gouin F, Tétreau R, Honoré C, Coindre JM, Ray-Coquard I, Bonvalot S, Blay JY. Fayet Y, et al. Among authors: dalban c. Cancers (Basel). 2022 May 25;14(11):2620. doi: 10.3390/cancers14112620. Cancers (Basel). 2022. PMID: 35681600 Free PMC article.
Ribosome biogenesis-based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group.
Mourksi NE, Dalban C, Colombe-Vermorel A, Odeyer L, Simioni V, Frenel JS, Fabbro M, Bazan F, Abadie-Lacourtoisie S, Coquan E, Martinez S, Garin G, Tabone-Eglinger S, Treilleux I, Chabaud S, Pérol D, Ray-Coquard I, Heudel PE, Diaz JJ, Marcel V. Mourksi NE, et al. Among authors: dalban c. Mol Oncol. 2023 Jan;17(1):27-36. doi: 10.1002/1878-0261.13340. Epub 2022 Dec 7. Mol Oncol. 2023. PMID: 36370117 Free PMC article.
Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
Rassy E, Dalban C, Colomba E, Derosa L, Alves Costa Silva C, Negrier S, Chevreau C, Gravis G, Oudard S, Laguerre B, Barthelemy P, Goupil MG, Geoffrois L, Rolland F, Thiery-Vuillemin A, Joly F, Ladoire S, Tantot F, Escudier B, Albiges L. Rassy E, et al. Among authors: dalban c. Clin Genitourin Cancer. 2022 Oct;20(5):488-494. doi: 10.1016/j.clgc.2022.07.003. Epub 2022 Jul 10. Clin Genitourin Cancer. 2022. PMID: 35977881 Clinical Trial.
Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study.
Carril-Ajuria L, Desnoyer A, Meylan M, Dalban C, Naigeon M, Cassard L, Vano Y, Rioux-Leclercq N, Chouaib S, Beuselinck B, Chabaud S, Barros-Monteiro J, Bougoüin A, Lacroix G, Colina-Moreno I, Tantot F, Boselli L, De Oliveira C, Fridman WH, Escudier B, Sautes-Fridman C, Albiges L, Chaput-Gras N. Carril-Ajuria L, et al. Among authors: dalban c. J Immunother Cancer. 2022 May;10(5):e004885. doi: 10.1136/jitc-2022-004885. J Immunother Cancer. 2022. PMID: 35640928 Free PMC article. Clinical Trial.
48 results